{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:26:06Z","timestamp":1791379566263,"version":"4.3.3"},"reference-count":100,"publisher":"MedWorks Media","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>Introduction\nSince the last edition of the Black Book, several innovative agents have been approved or are poised to be approved in the coming year. These include novel antidepressants, the first muscarine agonist for the treatment of schizophrenia, the first psychedelic which may be approved for the treatment of PTSD (Post Traumatic Stress Disorder), and the first disease modifying drug for the treatment of Alzheimer\u2019s disease.\nThree new antidepressants have come to the market in the past 18 months. The first of those, Auvelity, the combination of bupropion and dextromethorphan, takes advantage of a pharmacokinetic and pharmacodynamic synergism between the two drugs. 85 Dextromethorphan has several pharmacodynamic properties including actions on the NMDA receptor and the Sigma 1 receptor, adding to the indirect norepinephrine agonist properties of bupropion. How Dextromethorphan is rapidly metabolized via the CYP2D6 isoenzyme to dextrophan that may have mu opioid agonist properties. The combination with bupropion, a CYP2D6 inhibitor, inhibits the metabolism of dextromethorphan allowing for more consistent therapeutic levels. The combination of dextromethorphan 45 mg twice per day and bupropion SR 105 mg twice daily appears to be more effective than an equivalent dose of bupropion alone both in speeding up antidepressant response and achieving remission. However, it\u2019s not clear at this time how the combination would compare with a more typical dose of bupropion of 300\u2013450 milligrams a day range. The phase III program for Auvelity, showed that the drug was well tolerated with the most common side effects being dizziness, headache, and dry mouth. 86\nAnother novel antidepressant agent approved in 2023 is zuranolone (Zurzuvae). Zuranolone is an oral analog of IV brexanalone, and like brexanolone, was approved for the treatment of post-partum depression. 83 The advantages of zuranolone over brexanalone are many. While brexanolone is a 60-hour intravenous infusion that must be administered in a health care facility, zuranolone is a once\/day oral medication that is usually taken at home. Like brexanolone, and unlike most antidepressants, zuranolone has a short course of treatment, lasting just 14 days. Zuranolone\u2019s, as does brexanolone, is thought to act primarily as allosteric modulator of the GABA-a receptors. Despite only 14 days of treatment, zuranolone produced in depression in post-partum patients a clinically and significantly meaningful improvement at day 15 and continued to day 45 or 1 month past the end of treatment. Zuranolone is a schedule IV drug. The most common side effect in clinical trials was somnolence with 36% of participants reporting this side effect vs only 6% of those on placebo. 84 Other common side effects included dizziness, diarrhea and fatigue. While the FDA declined to approve zuranolone as monotherapy or as an adjunctive treatment to standard antidepressants in major depression itself, there are positive studies in non-post-partum major depression albeit with smaller effect sizes and less consistent duration of activity. It is likely that zuranolone will continue to be studied in other depressive syndromes such as depression with anxious distress.\nThe third \u201cnew\u201d antidepressant approved late 2023 was gepirone (Exxua). Gepirone is not exactly a new or novel antidepressant and originally sought approval in the US about 20 years ago. 88 There had been two positive studies of gepirone during the original NDA application but also a number of failed, negative, or non-informative studies as well. Thus, the FDA declined to originally approve the drug. However, failed and negative trials are common with antidepressants and after much internal debate, the FDA ultimately agreed to approve the drug based on the positive trials and a relatively favorable side effect profile. Gepirone, like buspirone, is a partial agonist of the 5HT1a receptor and a 5HT2 antagonist. As such, gepirone does not tend to be associated with sexual side effects, weight gain, or sedation. The most common side effects are dizziness, nausea, and insomnia which tend to improve in many patients over time.\nSecond generation antipsychotics (SGAs) continue to be the only class of agents [other than esketamine (Spravato)] approved in adjunctive treatment of resistant major depression. In addition to olanzapine (combined with fluoxetine; Symbyax), aripiprazole (Abilify), quetiapine (Seroquel), brexpiprazole (Rexulti), cariprazine (Vraylar) became the latest SGA to be approved in 2022. 90 Adjunctive cariprazine at 1.5 mg daily was significantly more effective than adjunctive placebo in patients with MDD who had failed to achieve an adequate response with an antidepressant alone after 6 weeks of treatment. Interestingly, a 3 mg dose of cariprazine was less consistently effective. 91 The major advantage of cariprazine over some of the other approved adjunctive SGA\u2019s is easy dosing, with the starting 1.5 mg dose being the optimal therapeutic dose for most people, and a lower metabolic side effect burden with most subjects having limited or no weight gain in short term trials. The most common side effect were akathisia\/restlessness, fatigue, and nausea. Lumateperone (Caplyta) is also has positive phase III data in the adjunctive treatment of major depression and is expective file for approval in late 2024.\nAnother recent major development in psychopharmacology is the reemergence of psychedelics in the treatment of psychiatric disorders. The first of these is MDMA (phenethylamine 3,4-methylenedioxymethamphetamine) assisted psychotherapy for the treatment of PTSD. A New Drug Application (NDA) was accepted by the FDA for MDMA in the treatment of PTSD in late 2023. 87 Because the drug is being fast tracked as a \u201cbreakthrough\u201d treatment by the FDA, it was expected to see approval in the summer of 2024. The phase II and III data for MDMA assisted psychotherapy in the treatment of PTSD have been quite consistent and impressive. However, independent reviews have pointed to significant deficiencies in these studies including the bias introduced because of functional unblinding; virtually all patients in psychedelic studies can guess whether they got the active drug or placebo. The functional unblinding, the lack of standardization of adjunctive psychotherapy as well as the abuse potential of MDMA, may delay an FDA approval. The typical regimen in these trials included 3 preparatory psychotherapy sessions followed by once\/month dosing sessions (lasting about 8 hours) and using doses of 120\u2013160 mg in a split dose. There were typically 3 monthly dosing sessions, each followed by 3 integrative psychotherapy sessions to help subjects process and understand their experiences during the dosing sessions. In the most recent phase 3 trials, over 70% of subjects no longer met criteria for PTDS compared to 46% of those treated with psychotherapy and placebo alone. 89 The only approved medications for treating PTSD are two SSRIs, paroxetine and sertraline. These drugs effect only some dimensions of PTSD with only 20\u201330% achieving a remission level response with these drugs. Thus, MDMA assisted psychotherapy appears to achieve much higher levels of remission and response than has been true for the SSRIs. Since MDMA is not taken continuously, side effects from MDMA tend to be short lived. Side effects have included muscle tightness, nausea, diminished appetite, excessive sweating, feeling cold and dizziness among others. Since MDMA is currently a schedule I drug, it is likely that a rigorous Risk Evaluation Mitigation (REMs) program will be put in place and a limited number of centers and clinicians will be designated to perform MDMA assisted psychotherapy for PTSD. In addition to MDMA, psilocybin-assisted psychotherapy is in phase 3 trials for treating resistant depression but unlikely to be available before late 2025 at the earliest.\nAn argument can be made that there has not been a truly novel antipsychotic since the introduction of clozapine in the US in 1990. All first-generation antipsychotics have been dopamine 2 antagonists and second-generation drugs have involved some ratio of 5HT2 antagonism to D2 blockade. In 2023, the FDA accepted the application of xenomaline\/tropsium (KarXT) which may become the first muscarinic M1M4 agonist approved for the treatment of schizophrenia. 82 , 83 Tropsium is added as a muscarine antagonist to block the peripheral cholinergic effects of a muscarine agonist. Xenomaline\/tropsium appears to be effective in treating both positive and negative symptoms of schizophrenia. In a phase 3 study of 407 patients with schizophrenia, xenomaline\/tropsium at doses of xenomaline\/50 mg\/tropsium 20 mg twice daily up to 125 mg\/30 mg twice daily was significantly more effective than placebo in treating both and negative symptoms over 5 weeks of treatment. As would be expected, the side effect profile of xenomaline\/tropsium is very different that all currently available antipsychotics. There is no risk of EPS as it is not a dopamine antagonist, and xenomaline\/tropsium is not associated with significant metabolic effects. The side effects are cholinergic in nature and include constipation, dry mouth, and nausea. A decision is expected in September of 2024.\nThe year 2023 also saw the approval of the first disease modifying drug in the treatment of Alzheimer\u2019s disease, lecanemab (Lequembi). While acetylcholinesterase inhibitors and memantine have been available for decades, these drugs modestly improve cognition in Alzheimer\u2019s disease patients and do not alter the progressive course of the illness. Lecanemab is an IV monoclonal antibody that targets the removal of beta-amyloid in the brain as well proto-fibrils that are also known to be toxic to neuronal tissue. When given early in the course of the illness, patients treated with Lecanemab showed 27% less decline on some measures of cognition and function than did patients treated with a placebo over 18 months (about 1 and a half years). It is not known whether treatment for longer than 18 months would show lesser or greater decline over time. However, there are simulation studies that suggest that Lecanemab may modestly reduce the number of patients who progress to severe Alzheimer\u2019s disease and require institutional care. The standard dose is 10 mg\/kg given via IV over one hour every 2 weeks for 18 months. Lecanemab is typically administered in an infusion center so that side effects can be monitored. The most serious side effects of Lecanemab are amyloid related imaging abnormalities (ARIA) that are associated with brain edema and microhemorrhages. ARIA can occur in up to 15% of patients. More common side effects are headache and nausea.\nWhile it remains to be seen how useful these new agents will be in clinical practice, they do represent an approach to treating neuropsychiatric disorders that are a notable departure from the pharmacotherapy of the past half century. It seems likely that some patients who have not been able to respond to or tolerate traditional pharmacotherapy will find hope in these new medications.<\/jats:p>","DOI":"10.64719\/pb.4493","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:39:16Z","timestamp":1761046756000},"page":"8-59","source":"Crossref","is-referenced-by-count":11,"title":["The Black Book of Psychotropic Dosing and Monitoring"],"prefix":"10.64719","volume":"54","author":[{"given":"Charles","family":"DeBattista","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan F","family":"Schatzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Greenblatt DJ, Harmatz JS, Shader RI. Update on Psychotropic Drug Prescribing in the United States: 2014\u20132015. J Clin Psychopharmacol. 2018;38(1):1\u20134. doi: 10.1097\/JCP.0000000000000831. doi: PMID: 2921538.","DOI":"10.1097\/JCP.0000000000000831"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Daly EJ, Singh JB, Fedgchin M, Cooper K, Lim P, Shelton RC, Thase ME, Winokur A, Van Nueten L, Manji H, Drevets WC. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2018;75(2):139\u2013148. doi: 10.1001\/jamapsychiatry.2017.3739. doi: PMID: 29282469; PMCID: PMC583857.","DOI":"10.1001\/jamapsychiatry.2017.3739"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Fedgchin M, Trivedi M, Daly EJ, Melkote R, Lane R, Lim P, Vitagliano D, Blier P, Fava M, Liebowitz M, Ravindran A, Gaillard R, Ameele HVD, Preskorn S, Manji H, Hough D, Drevets WC, Singh JB. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1) Int J Neuropsychopharmacol. 2019;22(10):616\u2013630. doi: 10.1093\/ijnp\/pyz039. doi: PMID: 31290965; PMCID: PMC6822141.","DOI":"10.1093\/ijnp\/pyz039"},{"key":"ref4","unstructured":"Tibensky BN, de L\u00e9s\u00e9leuc L, Perras C, Picheca L. Esketamine for Treatment-Resistant Depression. 2019 Apr 1. In: CADTH Issues in Emerging Health Technologies. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016\u2013. 176 PMID: 31211546."},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Faden J, Citrome L. Intravenous brexanolone for postpartum depression: what it is, how well does it work, and will it be used. Ther Adv Psychopharmacol. 2020 doi: 10.1177\/2045125320968658. 10:2045125320968658. doi: PMID: 33224470; PMCID: PMC765687.","DOI":"10.1177\/2045125320968658"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Leader LD, O\u2019Connell M, VandenBerg A. Brexanolone for Postpartum Depression: Clinical Evidence and Practical Considerations. Pharmacotherapy. 2019;39(11):1105\u20131112. doi: 10.1002\/phar.2331. doi: Epub 2019 Oct 7. PMID: 3151424.","DOI":"10.1002\/phar.2331"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Zheng W, Cai DB, Zheng W, Sim K, Ungvari GS, Peng XJ, Ning YP, Wang G, Xiang YT. Brexanolone for postpartum depression: A meta-analysis of randomized controlled studies. Psychiatry Res. 2019;279:83\u201389. doi: 10.1016\/j.psychres.2019.07.006. doi: Epub 2019 Jul 4. PMID: 3132337.","DOI":"10.1016\/j.psychres.2019.07.006"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Garnock-Jones KP. Cariprazine: A Review in Schizophrenia. CNS Drugs. 2017;31(6):513\u2013525. doi: 10.1007\/s40263-017-0442-z. doi: PMID: 2856061.","DOI":"10.1007\/s40263-017-0442-z"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Saraf G, Pinto JV, Yatham LN. Efficacy and safety of cariprazine in the treatment of bipolar disorder. Expert Opin Pharmacother. 2019;20(17):2063\u20132072. doi: 10.1080\/14656566.2019.1660319. doi: Epub 2019 Oct 23. PMID: 31644326.","DOI":"10.1080\/14656566.2019.1660319"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Corponi F, Fabbri C, Bitter I, Montgomery S, Vieta E, Kasper S, Pallanti S, Serretti A. Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. Eur Neuropsychopharmacol. 2019;29(9):971\u2013985. doi: 10.1016\/j.euroneuro.2019.06.008. doi: Epub 2019 Jun 27. PMID: 31255396.","DOI":"10.1016\/j.euroneuro.2019.06.008"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Blair HA. Lumateperone: First Approval. Drugs. 2020;80(4):417\u2013423. doi: 10.1007\/s40265-020-01271-6. doi: PMID: 3206088.","DOI":"10.1007\/s40265-020-01271-6"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Rahman T. Should Trackable Pill Technologies Be Used to Facilitate Adherence Among Patients Without Insight. AMA J Ethics. 2019;21(4):E332\u2013E336. doi: 10.1001\/amajethics.2019.332. doi: PMID: 3101242.","DOI":"10.1001\/amajethics.2019.332"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Zhou M, Derakhshanian S, Rath A, Bertrand S, DeGraw C, Barlow R, Menard A, Kaye AM, Hasoon J, Cornett EM, Kaye AD, Viswanath O, Urits I. Asenapine Transdermal Patch for the Management of Schizophrenia. Psychopharmacol Bull. 2020;50(4):60\u201382. PMID: 33012873; PMCID: PMC7511145.","DOI":"10.64719\/pb.4373"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Markovic M, Gallipani A, Patel KH, Maroney M. Brexpiprazole. Ann Pharmacother. 2017;51(4):315\u2013322. doi: 10.1177\/1060028016678262. doi: Epub 2016 Dec 15. PMID: 28228056.","DOI":"10.1177\/1060028016678262"},{"key":"ref15","unstructured":"Daghistani N, Rey JA. Invega Trinza: The First Four-Times-a-Year, Long-Acting Injectable Antipsychotic Agent. P T. 2016;41(4):222\u2013227. PMID: 27069340; PMCID: PMC4811251."},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Frampton JE. Aripiprazole Lauroxil: A Review in Schizophrenia. Drugs. 2017;77(18):2049\u20132056. doi: 10.1007\/s40265-017-0848-4. doi: PMID: 29177572.","DOI":"10.1007\/s40265-017-0848-4"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Jann MW, Penzak SR. Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents. CNS Drugs. 2018;2018;3232(3)(6):241\u2013257. 603. doi: 10.1007\/s40263-018-0508-6. doi: Erratum in: CNS Drugs. PMID: 29569082.","DOI":"10.1007\/s40263-018-0508-6"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Meyer JM. Converting oral to long-acting injectable antipsychotics: a guide for the perplexed. CNS Spectr. 2017;22(S1):14\u201328. doi: 10.1017\/S1092852917000840. doi: Erratum in: CNS Spectr 2018;23(2):186. PMID: 2935012.","DOI":"10.1017\/S1092852917000840"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Tarakad A, Jimenez-Shahed J. VMAT2 Inhibitors in Neuropsychiatric Disorders. CNS Drugs. 2018;32(12):1131\u20131144. doi: 10.1007\/s40263-018-0580-y. doi: PMID: 30306450.","DOI":"10.1007\/s40263-018-0580-y"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Peckham AM, Nicewonder JA. VMAT2 Inhibitors for Tardive Dyskinesia-Practice Implications. J Pharm Pract. 2019;32(4):450\u2013457. doi: 10.1177\/0897190018756512. doi: Epub 2018 Feb 18. PMID: 2945557.","DOI":"10.1177\/0897190018756512"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Han Y, Yuan K, Zheng Y, Lu L. Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders. Neurosci Bull. 2020;36(4):432\u2013448. doi: 10.1007\/s12264-019-00447-9. doi: Epub 2019 Nov 28. PMID: 31782044; PMCID: PMC7142186.","DOI":"10.1007\/s12264-019-00447-9"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Coleman PJ, Gotter AL, Herring WJ, Winrow CJ, Renger JJ. The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia. Annu Rev Pharmacol Toxicol. 2017;57:509\u2013533. doi: 10.1146\/annurev-pharmtox-010716-104837. doi: PMID: 2786054.","DOI":"10.1146\/annurev-pharmtox-010716-104837"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Murphy P, Moline M, Mayleben D, Rosenberg R, Zammit G, Pinner K, Dhadda S, Hong Q, Giorgi L, Lemborexant Satlin A. A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study. J Clin Sleep Med. 2017;13(11):1289\u20131299. doi: 10.5664\/jcsm.6800. doi: PMID: 29065953; PMCID: PMC565647.","DOI":"10.5664\/jcsm.6800"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Rosenberg R, Murphy P, Zammit G, Mayleben D, Kumar D, Dhadda S, Filippov G, LoPresti A, Moline M. Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial. JAMA Netw Open. 2019;2(12):e1918254. doi: 10.1001\/jamanetworkopen.2019.18254. doi: Erratum in: JAMA Net.","DOI":"10.1001\/jamanetworkopen.2019.18254"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, Markowitz JC, Ninan PT, Kornstein S, Manber R, Thase ME, Kocsis JH, Keller MB. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573\u2013583. doi: 10.1016\/s0006-3223(02)01866-8. doi: Erratum in: Biol Psychiatry. 2003;54(5):585. PMID: 1294688.","DOI":"10.1016\/s0006-3223(02)01866-8"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports. 1962;10:199\u2013812.","DOI":"10.2466\/pr0.1962.10.3.799"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Guy W, editor. Washington, DC: US Department of Health, Education, and Welfare; 1976. ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76\u2013338.","DOI":"10.1037\/e591322011-001"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Spitzer RL, Kroenke K, Williams JB, L\u00f6we B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092\u20131097. doi: 10.1001\/archinte.166.10.1092. doi: PMID: 1671717.","DOI":"10.1001\/archinte.166.10.1092"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606\u2013613. doi: 10.1046\/j.1525-1497.2001.016009606.x. doi: PMID: 11556941; PMCID: PMC149526.","DOI":"10.1046\/j.1525-1497.2001.016009606.x"},{"key":"ref30","unstructured":"Montvale, NJ: PDR Network; 2020. Physicians\u2019 desk reference."},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patient. Lancet. 2000;355:1048\u20131052.","DOI":"10.1016\/S0140-6736(00)02035-3"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshiminarayanan M, the Ziprasidone Study Group Ziprasidone 80 mg\/day and 160 mg\/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology. 1999;20(5):491\u2013505.","DOI":"10.1016\/S0893-133X(98)00090-6"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Seeger TF, Seymour PA, Schmidt AW et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmocol Exp Ther. 1995;275(1):101\u2013113.","DOI":"10.1016\/S0022-3565(25)12023-5"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Emrich HM, Dose M, von Zerssen D. The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders. J Affect Disord. 1985;8:243\u2013250.","DOI":"10.1016\/0165-0327(85)90022-9"},{"key":"ref35","unstructured":"Cabrera J, Albrecht J, M\u00fcller-Oerlinghausen B. Combined preventive treatment of recurrent manic-depressive disease with lithium and carbamazepine or oxcarbazepine. Nervenarzt. 1987;58:245\u2013249."},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Shorvon S. Oxcarbazepine: a review [editorial] Seizure. 2000;9:75\u201379.","DOI":"10.1053\/seiz.2000.0391"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Sim A. Rivastigmine: a review. Hosp Med. 1999;60(10):731\u2013735.","DOI":"10.12968\/hosp.1999.60.10.1217"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Forette F, Anand R, Gharabawi G. A phase II study in patients with Alzheimer\u2019s disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon) Eur J Neurol. 1999;6(4):423\u2013429.","DOI":"10.1046\/j.1468-1331.1999.640423.x"},{"key":"ref39","unstructured":"Janssen; 2001. Galantimine (Reminyl) package insert."},{"key":"ref40","unstructured":"Physicians\u2019 Desk Reference. 55th. Montvale, NJ: Medical Economics Co; 2001."},{"key":"ref41","unstructured":"Fuller MA, Sajatovic A. Psychotropic Drug Information Handbook. Hudson, OH: Lexi-Comp, Inc; 2001."},{"key":"ref42","unstructured":"Olin BR, Hebel SK, Dombek CE, editors. Facts and Comparisons. 1997 St Louis, Mo: Facts and Comparisons."},{"key":"ref43","unstructured":"American Hospital Formulary Service. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists; 2000."},{"key":"ref44","unstructured":"Taylor; 1998. Droperidol (Inapsine) package insert."},{"key":"ref45","unstructured":"Eli Lilly; 2000. Fluoxetine (Sarafem) package insert."},{"key":"ref46","unstructured":"Oxford; 1999. Isocarboxazid (Marplan) package insert."},{"key":"ref47","unstructured":"Pfizer; 2001. Ziprasidone (Geodon) package insert."},{"key":"ref48","unstructured":"DeVane CL, Javecke CR. In: Applied Pharmacokinetics; Principles of Therapeutic Drug Monitoring. Vancouver, BC: Applied Therapeutics; 1992. Cyclic antidepressants; pp. 1\u201347."},{"key":"ref49","unstructured":"Toney G, Ereshefsky L. In: Therapeutic Drug Monitoring. Norwalk, Conn: Appleton and Lange; 1995. Cyclic antidepressants; pp. 411\u2013449."},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Pollock B, Perel JM. Tricyclic antidepressants: contemporary issues for therapeutic practice. Can J Psychiatry. 1989;34(6):609\u2013617.","DOI":"10.1177\/070674378903400622"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Stern R, Marks IM, Mawson D, Luscombe DK. Clomipramine and exposure for compulsive rituals: II. Plasma levels, side effects and outcome. Br J Psychiatry. 1980;136:161\u2013166.","DOI":"10.1192\/bjp.136.2.161"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Nelson J, Jatlow PI, Quinlan DM, Bowers MB., Jr Desipramine plasma concentration and antidepressant response. Arch Gen Psychiatry. 1982;12:1419\u20131422.","DOI":"10.1001\/archpsyc.1982.04290120049010"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Glassman AH, Perel JM, Shostak M, Kantor SJ, Fleiss JL. Clinical implications of imipramine plasma levels for depressive illness. Arch Gen Psychiatry. 1977;34:197\u2013204.","DOI":"10.1001\/archpsyc.1977.01770140087010"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"APA Task Force. Tricyclic antidepressants\u2014blood level measurements and clinical outcome: an APA Task Force report. Am J Psychiatry. 1985;142(2):155\u2013162. Task Force on the Use of Laboratory Tests in Psychiatry. Revie.","DOI":"10.1176\/ajp.142.2.155"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Baumann P. Pharmacology and pharmacokinetics of citalopram and other SSRIs. Int Clin Psychopharmacol. 1996;11(suppl 1):5\u201311.","DOI":"10.1097\/00004850-199603001-00002"},{"key":"ref56","unstructured":"DeVane CL. Pharmacogenetics and drug metabolism of newer antidepressant agents. J Clin Psychiatry. 1994;55(12 suppl):38\u201345. discussion 46\u201347. Revie."},{"key":"ref57","unstructured":"DeVane CL. Differential pharmacology of newer antidepressants. J Clin Psychiatry. 1998;59(suppl 20):85\u201393."},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Nemeroff C, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry. 1996;153(3):311\u2013320.","DOI":"10.1176\/ajp.153.3.311"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Ketter TA, Flockhart DA, Post RM et al. The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol. 1995;15(6):387\u2013398. Revie.","DOI":"10.1097\/00004714-199512000-00002"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994;270(1):414\u2013423.","DOI":"10.1016\/S0022-3565(25)22379-5"},{"key":"ref61","unstructured":"Caroulo D, Shader RI, Greenblatt DJ, Creelman W. Drug Interactions in Psychiatry. 2nd. Baltimore, Md: Williams and Wilkins; 1994."},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Michalets EL. Update: Clinically significant cytochrome P-450 drug interactions. Pharmacotherapy. 1998;18(1):84\u2013112.","DOI":"10.1002\/j.1875-9114.1998.tb03830.x"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Shen WW. Cytochrome P450 monooxygenases and interactions of psychotropic drugs: a five-year update. Int J Psychiatry Med. 1995;25(3):277\u2013290.","DOI":"10.2190\/29NP-2XPN-X0ME-MQWU"},{"key":"ref64","unstructured":"Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry. 1996;57(suppl 11):12\u201325."},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Finley PR, Warner MD, Peabody CA. Clinical relevane of drug interactions with lithium. Clin Pharmacokinetics. 1995;29(3):172\u2013191.","DOI":"10.2165\/00003088-199529030-00004"},{"key":"ref66","unstructured":"DeVane CL, Nemeroff CB. Psychotropic drug interactions. Primary Psychiatry. 2000;7(10):40\u201368."},{"key":"ref67","unstructured":"DeVane CL, Markowitz JS. Avoiding psychotropic drug interactions in the cardiovascular patient. Bull Menninger Clinic. 2000;64(1):49\u201359."},{"key":"ref68","unstructured":"Jefferson J, Griest JH, Ackerman DL, Carroll JA, editors. In: Lithium Encyclopedia for Clinical Practice. Washington, DC: American Psychiatric Press; 1987. Lithium: an overview; pp. 13\u201321."},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Bowden C, Brugger AM, Swann AC et al. Efficacy of diavalproex vs lithium and placebo in the treatment of mania. JAMA. 1994;271(12):918\u2013924.","DOI":"10.1001\/jama.1994.03510360044034"},{"key":"ref70","unstructured":"Ketter TA, Post RM. Clinical pharmacology and pharmacokinetics of carbamazepine. In: Joffe RT, Calabrese JR, editors. In: Anticonvulsants in Mood Disorders. New York, NY: Marcel Dekker; 1994. pp. 147\u2013188."},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Pellock JM, Willmore LJ. A rational guide to routine blood monitoring in patients receiving antiepileptic drugs. Neurolog. 1991;41(7):961\u2013964.","DOI":"10.1212\/WNL.41.7.961"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Seymour JF. Carbamazepine overdose: features of 33 cases. Drug Saf. 1993;8(1):81\u201388.","DOI":"10.2165\/00002018-199308010-00010"},{"key":"ref73","unstructured":"Schatzberg A, Cole J, DeBattista C. In: Manual of Clincal Psychopharmacology. Washington, D.C.: American Psychiatric Press; 1997. Mood stabilizers; pp. 181\u2013222."},{"key":"ref74","unstructured":"Kirkwood CK, Hayes P. In: Pharmacotherapy A Pathopsysiologic Approach. New York, NY: Elsevier Science Publishing; 1989. Anxiety disorders; pp. 1443\u20131462."},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Lader M, Scotto JC. A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder. Psychopharmacology. 1998;139:402\u2013406.","DOI":"10.1007\/s002130050731"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Ferreri M, Hantouche EG. Recent clinical trials of hydroxyzine in generalized anxiety disorder. Acta Psychiatr Scand. 1998;98(suppl 393):102\u2013108.","DOI":"10.1111\/j.1600-0447.1998.tb05974.x"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Kerry RJ, McDermott CM. Medazepam compared with amylobarbitone in treatment of anxiety. Br Med J. 1971;1(741):151\u2013152.","DOI":"10.1136\/bmj.1.5741.151"},{"key":"ref78","unstructured":"Owens MJ, Risch SC. Atypical antipsychotics. In: Schatzberg AF, Nemeroff CB, editors. Textbook of Psychopharmacology. 2nd. Washington, DC: American Psychiatric Press; 1998. pp. 323\u2013348."},{"key":"ref79","unstructured":"Ereshefsky L, Overman GP, Karp JK. Current psychotropic dosing and monitoring guidelines. Primary Psychiatry. 1996;7:21\u201345."},{"key":"ref80","unstructured":"Schatzberg AF, Cole J, DeBattista C. In: Manual of Clinical Psychopharmacology. Washington, DC: American Psychiatric Press; 1998. Antipsychotic drugs; pp. 113\u2013180."},{"key":"ref81","unstructured":"Prakash C, Kamel A, Anderson W, Howard H. Metabolism and excretion of the novel antipsychotic drug ziprasidone in rats after oral administration of a mixture of 14C- and 3H-labeled ziprasidone. Drug Metab Dispos. 1997;25(2):206\u2013218."},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"Ereshefsky L, Richards AL. Psychoses. In: Koda-Kimble MA, Yound LY, editors. Applied Therapeutics: The Clinical Use of Drugs. 5th. Vancouver, Wash: Applied Therapeutics; 1992. pp. 1\u201343.","DOI":"10.1007\/978-1-349-13175-4_56"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"Ereshefsky L, Toney G, Saklad SR, Anderson C, Seidel D. A loading-dose strategy for converting from oral to depot neuroleptic. Hosp Community Psychiatry. 1993;44(12):1155\u20131161.","DOI":"10.1176\/ps.44.12.1155"},{"key":"ref84","unstructured":"Gimenez-Roldan S. Ropinirol: a new dopamine agonist in the treatment of Parkinson\u2019s disease. J Neurolgia. 1997;12(8):354\u2013361."},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"Bennett JP, Jr., Piercey MF. Pramipexole\u2014a new dopamine agonist for the treatment of Parkinson\u2019s disease. J Neurol Sci. 1999;163:25\u201331.","DOI":"10.1016\/S0022-510X(98)00307-4"},{"key":"ref86","unstructured":"Crismon ML, Dorson PG. Schizophrenia. In: DiPiro JT, Talbert RL, Hayes PE, editors. Pharmacotherapy. East Norwalk, Conn: Appleton and Lange; 1993. pp. 1020\u20131043."},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"Tarsy D. Movement disorders with neuroleptic drug treatment. Symposium on clinical psychopharmacology. J Psychiatr Clin North Am. 1984;7(3):453\u2013471.","DOI":"10.1016\/S0193-953X(18)30744-5"},{"key":"ref88","unstructured":"DeBattista C, Schatzberg AF. Current psychotropic dosing and monitoring guidelines. Primary Psychiatry. 1999;6(3):65\u2013102."},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"McNeely W, Benfield P. Orlistat. Drugs. 1998;56(2):241\u2013249. discussion 250. Revie.","DOI":"10.2165\/00003495-199856020-00007"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"McNeely W, Goa KL. Sibutramine. A review of its contribution to the management of obesity. Drugs. 1998;56(6):1093\u20131124.","DOI":"10.2165\/00003495-199856060-00019"},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"Kolanowski J. A risk-benefit assessment of anti-obesity drugs. Drug Saf. 1999;20(2):119\u2013131.","DOI":"10.2165\/00002018-199920020-00003"},{"key":"ref92","doi-asserted-by":"crossref","unstructured":"Ferraro L, Antonelli T, O\u2019Connor WT, Tanganelli S, Rambert FA, Fuxe K. Modafinil: an antinarcoleptic drug with a different neurochemical profile to d-amphetamine and dopamine uptake blockers. Biol Psychiatry. 1997;42:1181\u20131183.","DOI":"10.1016\/S0006-3223(97)00353-3"},{"key":"ref93","doi-asserted-by":"crossref","unstructured":"Giacobini E. Invited review: cholinesterase inhibitors for Alzheimer\u2019s disease therapy: from tacrine to future applications. Neurochem Int. 1998;32:413\u2013419.","DOI":"10.1016\/S0197-0186(97)00124-1"},{"key":"ref94","doi-asserted-by":"crossref","unstructured":"Wagstaff AJ, Tacrine McTavish D. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer\u2019s disease. Drugs Aging. 1995;4(6):510\u2013540.","DOI":"10.2165\/00002512-199404060-00006"},{"key":"ref95","doi-asserted-by":"crossref","unstructured":"Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer\u2019s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia. 1996;7:293\u2013303.","DOI":"10.1159\/000106895"},{"key":"ref96","doi-asserted-by":"crossref","unstructured":"Doody RS. Clinical profile of donepezil in the treatment of Alzheimer\u2019s disease. Gerontology. 1999;45(suppl 1):23\u201332.","DOI":"10.1159\/000052761"},{"key":"ref97","doi-asserted-by":"crossref","unstructured":"Grossberg GT, Stahelin HB, Messina JC, Anand R, Veach J. Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications. Int J Geriatr Psychiatry. 2000;15:242\u2013247.","DOI":"10.1002\/(SICI)1099-1166(200003)15:3<242::AID-GPS110>3.0.CO;2-7"},{"key":"ref98","doi-asserted-by":"crossref","unstructured":"Bentham P, Gray R, Sellwood E, Raftery J. Effectiveness of rivastigmine in Alzheimer\u2019s disease. Improvements in functional ability remain unestablished [letter] BMJ. 1999;319:640\u2013641.","DOI":"10.1136\/bmj.319.7210.640a"},{"key":"ref99","doi-asserted-by":"crossref","unstructured":"McKeith IG, Grace JB, Walker Z et al. Rivastigmine in the treatment of dementia with lewy bodies: preliminary findings from an open trial. Int J Geriatr Psychiatry. 2000;15:387\u2013392.","DOI":"10.1002\/(SICI)1099-1166(200005)15:5<387::AID-GPS131>3.0.CO;2-9"},{"key":"ref100","doi-asserted-by":"crossref","unstructured":"Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429\u2013435.","DOI":"10.1192\/bjp.133.5.429"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:32:35Z","timestamp":1791315155000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/the-black-book-of-psychotropic-dosing-and-monitoring\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":100,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4493","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}